Sort
48,018 grants matching “immunotherapy”
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2013 · AI
Therapy and Prophylaxis for Genital Tract Infection
$1,000,000Dominick Auci · Therapyx, Inc. · R44 · FY2021 · AI
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · CA
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
$1,000,000Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2017 · AI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$1,000,000Pan Zheng · Oncoc4, Inc. · R44 · FY2022 · CA
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B
$1,000,000Eric Bruening · Tomegavax, Inc. · R44 · FY2019 · AI
Spatial and single cell analysis of tumor microenvironment by seqFISH+
$999,999Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2020 · CA
SIRPant Technology for anti-Cancer Immunity
$999,999Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA
Spatial and single cell analysis of tumor microenvironment by seqFISH+
$999,999Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2021 · CA
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry
$999,998Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2021 · AI
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
$999,997Gary G. Altman · Cambium Oncology Llc · R44 · FY2025 · CA
Development of GIFT4: a B cell focused immunotherapy for cancer
$999,997Paul Guyre · Celdara Medical, Llc · R44 · FY2018 · CA
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)
$999,996Zhiyong Yang · Fzata, Inc. · R44 · FY2021 · AI
Humanized monoclonal antibodies to treat mucormycosis
$999,975Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2024 · AI
HHSN261201400048C; TOPIC 309 ? ?DEVEL.OF.LOW COST,SMALLSAMPLE MULTI-ANAL.TECH.FORCANCER DIAGNOSIS,PROGNOSIS&EARLY DETECTION?;TITLE: DEPLOYMENT.OF.PROTOTYPE SYSTEM FOR DETECTION OF MULTI. ANAL. IN SMAL
$999,967Arthur Tinkelenburg · Enumeral Biomedical Corporation · N44 · FY2014 · CA
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
$999,960Tina Garyantes · Linnaeus Therapeutics Inc · R44 · FY2025 · CA
Modeling the ecology of tissue-resident T cells
$999,932Andrew Yates · Columbia University Health Sciences · U01 · FY2021 · AI
Novel IL-15 Superagonist Therapy for Bladder Cancer
$999,919Peter R Rhode · Altor Bioscience. Llc · R44 · FY2018 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer
$999,919John Lee · Altor Bioscience. Llc · R44 · FY2019 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer
$999,919Peter R Rhode · Altor Bioscience. Llc · R44 · FY2017 · CA
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
$999,893Bernhard Josef Hering · University Of Minnesota · U01 · FY2015 · AI
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
$999,883Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2021 · CA
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
$999,883Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2020 · CA
Herpes Simplex Immunotherapeutic Vaccine
$999,845Sean M. Sullivan · Vical, Inc. · R42 · FY2009 · AI
Development of a protein drug for pancreatic cancer treatment
$999,780Zhi-Ren Liu · Proda Biotech, Llc · R42 · FY2018 · CA